NetworkNewsWire Announces Publication Discussing Advanced Technology in Cannabinoid R&D
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 10/26/17 -- ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
The publication, titled, "Biotechs Develop Proprietary Systems to Drive CBD Research and Development," discusses biotech companies focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals.
To view the full publication, visit:
"One of the leading companies in this sector is (CSE: IN) (OTCQB: IMLFF) , which has created proprietary systems for bioinformatics and biosynthesis manufacturing of pharmaceutical-grade cannabinoids.
"These systems provide them with increased control over outcomes in their drive to create product of consistently high purity. This is critical in the emerging cannabinoid drug sector, where the Food and Drug Administration (FDA) has major concerns regarding the consistency of drugs and products manufactured from agricultural cannabis. Any biotech in this sector striving for approval from the FDA must ensure that its products are able to survive rigorous pharmaceutical testing and manufacturing standards.
"The company''s preclinical development pipeline includes INM-750 for the treatment of epidermolysis bullosa (EB), an orphan pediatric disease with no currently approved therapy. The potential global market revenues for this drug are estimated at $1 billion. INM-085, a second drug in development, is being studied as a treatment option for glaucoma, with its global market value of over $5 billion. More than three million Americans are estimated to be living with glaucoma, and over 120,000 have been blinded by this condition ()."
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed''s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.
For more information, visit .
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today''s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company''s SEC filings. These risks and uncertainties could cause the company''s actual results to differ materially from those indicated in the forward-looking statements.
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2017 - 05:30 Uhr
Sprache: Deutsch
News-ID 1526038
Anzahl Zeichen: 5732
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 476 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NetworkNewsWire Announces Publication Discussing Advanced Technology in Cannabinoid R&D
"
steht unter der journalistisch-redaktionellen Verantwortung von
NetworkNewsWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
